MIACALCIN (calcitonin salmon) by Viatris (2) is agonist. Approved for symptomatic paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase, urinary hydroxyproline excretion, postmenopausal osteoporosis in women greater than 5 years postmenopause and 2 more indications. First approved in 1995.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
MIACALCIN (calcitonin salmon) is a nasal spray that acts as a calcitonin receptor agonist, primarily targeting bone remodeling by inhibiting osteoclast activity. It is indicated for postmenopausal osteoporosis, Paget's disease of bone, and related conditions characterized by abnormal bone metabolism. The drug works by binding calcitonin receptors on osteoclasts and osteoblasts, reducing bone resorption and promoting bone preservation.
Small, contracted team focused on market maintenance rather than expansion as product approaches loss of exclusivity.
agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer…
Worked on MIACALCIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMIACALCIN offers limited career growth opportunity due to its approaching loss of exclusivity and minimal market traction (only 48 Part D claims annually). Positions on this product are primarily defensive—focused on maintaining relationships with remaining prescribers and managing transition to generic/biosimilar competition rather than driving market expansion or innovation.